Abstract Background Renal cell carcinoma (RCC) is a highly immunogenic cancer characterized by abundant CD8+ T cell infiltration, yet most patients do not achieve durable responses to immunotherapy. Notably, surgical removal of the primary tumor, even in metastatic disease, may enhance response to immunotherapy, an eff...
S. Schwartz, L. Wirth, Julia Walker et al.· The Oncologist· 0 citations
Hypoxia-inducible factor 2α (HIF-2α) is a central oncogenic driver in clear cell renal cell carcinoma (ccRCC) and a therapeutic target of the small-molecule inhibitor belzutifan. Genetic studies in murine models have suggested that hypoxia signaling may support T cell effector programs, raising concern that HIF-2α inhi...
Katrine N. Madsen, S. Kashima, H. Soulati et al.· Journal of Clinical Investig...· 0 citations
An in vitro RCC antigen model system was established to evaluate the impact of belzutifan on T-cell cytotoxicity and revealed that IL-2 and IFNG were among the most significantly downregulated genes in HIF2α knockout T cells.
S. Kashima, Katrine N. Madsen, H. Soulati et al.· The Oncologist· 0 citations
The findings suggest an ECM–CD44 axis linking tumor mesenchymal programs to M2-like polarization and increased macrophage infiltration in stromal and sarcomatoid areas compared to clear cell regions.
Katsuhiro Ito, S. Kashima, Rishabh Rout et al.· The Oncologist· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
